eXoZymes (EXOZ) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
INmune Bio (INMB) has outperformed eXoZymes (EXOZ) over the past year, losing 45.2% versus a loss of 81.8%. eXoZymes is the larger company by market cap ($27.4 million vs $25.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXOZ | INMB |
|---|---|---|
| Share price | $2.91 | $0.827 |
| Market cap | $27.42M | $25.60M |
| 1-day change | -14.05% | -7.50% |
| YTD return | -73.35% | -46.99% |
| 1-year return | -81.84% | -45.23% |
| 5-year return | — | -93.80% |
| EPS (TTM) | $-1.16 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $50.00K |
| Revenue growth (YoY) | — | +257.14% |
| Net income (latest FY) | $-9.16M | $-45.93M |
| Operating margin | — | -94766.00% |
| Net margin | — | -91866.00% |
| 52-week high | $16.16 | $2.60 |
| 52-week low | $2.81 | $0.8189 |
| Distance from 52-week high | -82.02% | -68.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | — | +746.43% |
| Average volume | 10.14K | 338.47K |
| Shares outstanding | 9.44M | 30.96M |
| Employees | 32 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed EXOZ by 36.6 percentage points over the past year.
About eXoZymes
EXOZ stock →eXoZymes, Inc. operates as a development stage biotechnology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 32 employees
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
EXOZ vs INMB FAQ
Which is bigger, eXoZymes or INmune Bio?
eXoZymes (EXOZ) is larger, with a market capitalization of $27.42M compared with $25.60M for INmune Bio (INMB).
Which stock has performed better over the past year, EXOZ or INMB?
INMB returned -45.23% over the past 12 months, compared with -81.84% for EXOZ (price return, excluding dividends). Past performance does not predict future results.
Are eXoZymes and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.